Abstract. Well-differentiated papillary and follicular thyroid carcinomas are the two most common types of thyroid cancer. Although cancerous cells in both types phenotypically resemble the epithelial follicular cell, the tumors display different histological characteristics and clinical outcomes. Molecular defects contributing to the separate development pathways remain largely unclear. We evaluated gene expression profiles to generate a detailed molecular characterization of the two tumor types, attempting to detect novel diagnostic and clinical markers. Gene expression profiling of 46 thyroid samples (16 papillary carcinomas, 13 follicular carcinomas and 17 normal thyroid specimens) was performed by using high-density human UniGene cDNA arrays. The identification of differentially expressed genes was based on a comparison of signal intensity ratios of tumor versus normal tissues. A cross-validation of individual filter-array hybridizations and real-time PCR analysis of selected genes were carried out to confirm data reproducibility and reliability. The majority of genes with altered expression were found in both papillary and follicular carcinomas, reflecting a close relationship between the two tumor types. However, 123 genes consisting of 45 known and 78 unknown genes were shown to be differentially expressed between papillary and follicular carcinomas. Follicular variants of papillary carcinoma, clustered together with classical papillary carcinoma, could be differentiated from follicular carcinoma. Our study revealed a set of genes differentiating follicular carcinoma from classical papillary carcinoma and follicular variant. The data generated in this study could serve as a useful source for further investigation of pathways of papillary and follicular differentiation of thyroid cancer.
Introduction
Thyroid cancer that originates from follicle cells of the thyroid can be subdivided into PTC, FTC and ATC (1) . PTC and FTC are the two most common types of thyroid malignancies, representing approximately 80% and 15% of all thyroid cancers, respectively (2). ATC is rare, accounting for approximately 1% of thyroid cancers. PTC and FTC are well-differentiated carcinomas and bear a favorable prognosis, whereas ATC is an undifferentiated tumor and aggressive. Despite arising from the same progenitor cell, the three tumor types differ in histological features and clinical behavior. PTC is characterized by papillary growth pattern, common presence of distinctive nuclear changes and metastasis to the regional lymph nodes. In contrast, FTC is characterized by follicular architecture (lack of papillae) and invasion into the capsule and/or blood vessels. The prognosis of FTC is in general less favorable than that of PTC. ATC that is believed to occur from a terminal dedifferentiation of previously undetected long-standing papillary or follicular thyroid carcinoma (3) has a rapid progression behavior and often manifests a distant dissemination at diagnosis. The most common sites of distant spread of ATC include lung, bone and brain. Although the three types of thyroid carcinomas are usually distinguishable on histopathological or cytological examination, the molecular basis of the phenotypes remains unclear. Differential diagnosis of atypical forms (e.g., follicular variant of PTC) is sometimes also difficult. Therefore, there is a need to characterize genetic alterations in these tumors and to search for new markers for amending differential diagnosis.
Molecular genetic studies have identified several common genetic changes associated with PTC, FTC and ATC. Alterations of the RET gene, which is mapped to 10q, are considered to play an important role in PTC development (4, 5) . On the other hand, the PAX8-PPARÁ1 fusion gene, resulting from the translocation t(2;3)(q13;p25), is implicated in the progression of FTC (6) . Genetic changes of several other genes, such as the RAS oncogene family (7, 8) , BRAF (9, 10) , p53 (3, 11, 12) , MDM2 (13) , AKT (14) and MET (15) , have also been found in a fraction of thyroid cancers including all the three tumor types. However, none of the molecular aberrations is convincingly linked to defined histological types of thyroid cancer and the precise mechanisms by which thyroid cancer develops through the papillary or follicular pathway remain unclear. Cytogenetic analyses showed that chromosome imbalances and allelic losses involve multiple chromosomes (16) (17) (18) (19) , indicating the presence of undetected genes contributing to the initiation and development of the thyroid malignancies of follicular cell derivation.
Examining tumors for alterations in genome-wide gene expression is a potentially useful approach to determining the detailed molecular characterization of tumors (20) . It could provide significant insight into tumorigenesis as well as facilitate diagnosis and thereby guide treatment. Recently, gene expression profiling based on array techniques has been used to study various tumors including thyroid carcinomas of follicular cell derivation (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . One of these studies directly compared two independent previous studies to reveal gene expression differences between PTC and FTC (27) . The present study analyzed gene expression profiles by using filter-based high-density cDNA arrays in a series of thyroid tissues including 16 PTCs, 13 FTCs and 17 normal thyroid samples. Despite a similar involvement of the majority of genes with altered expression in these tumors, a small number of genes were identified to be differentially expressed between the two major tumor types. The data may provide important clues to the development and progression of papillary and follicular thyroid tumors through separate pathways.
Materials and methods
Tissue samples. Forty-six deep-frozen thyroid samples, which were taken intraoperatively from 29 patients during primary thyroidectomy, were collected for this study after obtaining informed consent. According to WHO criteria, PTC was diagnosed in 16 patients, and FTC in 13 patients. The 16 PTCs included 11 classical papillary carcinomas and 5 follicular variants. Of the 13 FTCs, 10 had minimal invasions and 3 had wide invasions, one of which had anaplastic foci (Table I) . Table I. Clinical data of patients suffering from thyroid carcinomas.  -----------------------------------------------------------------------------------------------------Type  No.  Age/sex  Stage  Size (cm)  Histological variant  Lymph node metastases a  -----------------------------------------------------------------------------------------------------PTC  19 
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; F, female; M, male; CI, capsule invasion; VI, blood vessel invasion; MI, minimally invasive; WI, widely invasive.
a The data for extra-thyroidal extension are not available for all patients.
The tumor with anaplastic foci included in this study showed predominant follicular neoplastic growth, indicating a progression from FTC to ATC. The patients were euthyroid and had a normal value of thyroid-stimulating hormone (TSH). They were not treated with any drugs before surgery. Macroscopically unchanged surrounding thyroid tissue samples were obtained from 17 of these patients. To confirm the diagnoses, all tissue samples used for the array analyses were histologically reviewed by one senior pathologist (P.H.). Histological assessments were carried out according to the WHO classification (1, 31) . Frozen sections were taken from each tissue block and stained with hematoxylin and eosin (H&E). Representative areas containing >80% of tumor cells or only normal tissue were selected for isolating RNA.
RNA preparation and hybridization. Total RNA was extracted from frozen tissues by using TRI Reagent ® (Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer's protocol. The reverse transcription of total RNA into cDNA was performed as described in standardized protocols (Research Genetics, Huntsville, AL) with minor modifications. cDNA was synthesized from 2 μg of total RNA by using reverse transcriptase (Qiagen, Basel, Switzerland) in the presence of oligo-dT primer, nucleotide mix (Ambion, Austin) and ·-[
33 P]-dATP (3000 Ci/mmol, Amersham Pharmacia, UK). Labeled cDNA was purified with MicroSpin™ Columns S-300 (Amersham Pharmacia). High-density cDNA filters (RZPD library 956, Human Unigene Set 2) were obtained from the Resource Center of the German Human Genome Project (RZPD; www.rzpd.de). The filters contained a lowredundancy selection of 75,000 human IMAGE (integrated molecular analysis of genomes and their expression) cDNA clone sequences, including 12,000 known genes and 63,000 expressed sequence tags (EST), which were spotted in duplicate. The cDNA arrays were first used to screen for genome-wide gene expression profiles in 6 matched tumor/ normal samples that were obtained from 3 PTC and 3 FTC patients, respectively. Based on the initial results (described in detail in Data analysis), approximately 8,600 cDNA clones consisting of 2,900 known genes and 5700 ESTs were subsequently selected for constructing subarrays. Hybridization and washing were performed essentially following the manufacturer's instructions with modifications. Filter arrays were prehybridized in 15 ml MicroHyb (Research Genetics) and 7 μg of each of human Cot-1 DNA and poly-dA at 42˚C for 2 h. 33 P-labeled cDNA probes were denatured and then added to the prehybridization mixtures. Hybridization was carried out at 42˚C overnight.
As a control experiment to test the array reproducibility, we repeated hybridization for one sample on four different filter arrays in one experiment.
Data analysis. The cDNA array was visualized at 50-μm resolution and 16 bits on a phosphor-imaging system (Fuji, Japan) and interpreted using ArrayVision™ software (Version 5.1, www.imaging-research.com). The signal intensity of each spot on the array was calculated as the mean pixel value minus a local region background and then normalized to the mean of all spots on the array, which allows generating the mean intensity from multiple arrays and subsequent comparison of different hybridizations. For target selection to construct the subarray, signal intensity ratios of tumor versus corresponding normal tissue were calculated for each target on the array. If the signal intensity value of the average of the two replicates fell below a threshold of background at 0.02, the intensity value for that target was reset to a value of 0.02 in order to avoid negative or spuriously large ratio values. The fold change value was used to define gene expression level. A gene that had a ratio value of ≥2 was considered overexpressed, whereas one with a ratio of ≤0.5 was regarded as underexpressed. Targets were selected for constructing the subarray, if their ratios of tumor versus the corresponding normal tissue were consistently <0.5 or >2 in at least two of the three matched pairs for each tumor type.
The software GeneSight (BioDiscovery, Inc., Los Angeles, CA) was used for ratio calculation, clustering and statistical analyses including ANOVA, Student's t-test, and permutation t-test. For data analyses, we first performed ANOVA analysis to identify genes that exhibited significant expression differences between normal, PTC and FTC samples. To smooth the variation in gene expression among normal thyroid samples, signal intensity ratios of each tumor versus the median value of 17 normal samples were calculated for all genes. On the basis of gene expression ratios of tumor versus normal samples, we carried out fold change analysis to detect genes with ≥2-fold change. Student's t-test and permutation 2-sample t-test were used to compare the two main tumor groups (PTC vs. FTC) as well as PTC subtypes (classical vs. follicular variant) for statistical significances of the differentially expressed genes that were identified by ANOVA and fold change analyses. Permutation test is a statistical method, in which the significance level for each gene is determined by comparing its statistic to the permutation distribution of the tumor samples that were randomly divided into two groups for 10,000 times. Hierarchical clustering was used to classify the tumors on the basis of gene expression similarity.
Quantitative real-time PCR.
To confirm that the cDNA array data accurately reflect levels of transcripts, four genes (TG, PAX8, FN1 and CNN3) were subjected to the quantitative real-time PCR analysis in 12 random selected samples. Two μg of total RNA from tumors, normal tissues and the pool of normal samples were denatured at 65˚C for 5 min and then reverse-transcribed in a 20-μl reaction mixture containing 250 μM of each dNTP, 50 units of reverse transcriptase enzyme (Omniscript, Life Technologies), 100 ng/μl oligo (dT) 16 primers (Life Technologies), 1X PCR buffer, 2.0 mM MgCl 2 (Applied Biosystems, Inc., Foster City, CA) at 37˚C for 60 min.
The sequences of specific primers and TaqMan probes for CNN3 were as follows: forward, CCTTTTGACCAGACCA CAATTAGTC; reverse, TGTCTCTTCTGGTACCTGGTGC TA; probe, FAM-CATCCCTGCCTGGCTGGCTCCTAMRA. Assays-on-demand™ primers and probes, obtained from Applied Biosystems, Inc., were used for the other three genes (TG, PAX8 and FN1). These primers and probes were designed to work in the same cycling conditions (95˚C for 10 min followed by 40 cycles at 95˚C for 15 sec and 60˚C for 1 min) generating products with sizes 100-150 bp. ACTB (ß-actin) was tested as an endogenous control. Real-time PCR was carried out by means of an Applied Biosystems PRISM 7700 Sequence Detector and TaqMan ® reagents, according to the manufacturer's protocol. All samples were run in triplicate. Reactions omitting enzyme or RNA were used as negative controls. Relative transcript amounts of these genes were calculated by comparison with the pooled RNA of the 17 normal samples and normalized to ACTB in the reaction.
Results
Genes showing frequent expression change in both FTC and PTC. ANOVA analysis revealed approximately 1,950 cDNA targets displaying significant expression differences between PTC, FTC and normal thyroid samples. Fold change analysis detected 603 genes with at least 2-fold underexpression and 176 genes with at least 2-fold overexpression, which frequently occurred in papillary and/or follicular tumors (>40%). Although these genes were differentially expressed between tumor and normal samples, most of them showed no significant differences between the two types of thyroid carcinomas. This finding is consistent with the hypothesis that most gene expression alterations may be similarly involved in both PTC and FTC due to their close histological relationship.
The frequently deregulated genes identified in both tumor types fell into several functional categories including cell cycle, cell proliferation and differentiation, signal transduction, transcription and translation, cell-cell or cell-matrix interaction, and positive or negative regulation of tumor cells. The most frequently overexpressed genes, detected in ≥60% of PTC and/ or FTC, include those belonging to signal transduction (PTPRF and TBL2), cell cycle control (CDK5R1 and RBBP6), growth factor receptors (EGFR and PDGFRB) and transcriptional factors (ESR1). Some genes associated with cell-cell and cellmatrix interaction, including ITGAL, TNFAIP6 and MMP12, were also frequently overexpressed. The most commonly underexpressed genes observed in both tumors (≥60%) are associated with cell cycle, proliferation and differentiation (AKAP11, CCND3, RIP60 and TGFb1), signal transduction (ACK1, CARD6, GPR48, GRIN2D, MATK and PPP1R9B), transcription and translation regulation (MKRN3, ETV3 and SOX17), transport (ABCB1, BAP29 and STX3A), and immune response (IGHG3, IGKC and SIGIRR).
Strikingly, several members of the RAS oncogene pathway were frequently deregulated in both PTC and FTC. NRAS, RAB11B and RAB40C were overexpressed, while BRAF, RAB1A, RAP1A and RAGD were underexpressed. Some genes (e.g., MET and LGALS3) that have been reported to be involved in the development of thyroid tumors were also overexpressed in a portion of PTC and FTC specimens.
Some thyroid-specific genes, such as TG encoding thyroglobulin (the glycoprotein precursor of thyroid hormones) and PAX8 (a member of the PAX family that is able to activate expression of endogenous thyroid-specific genes including TG), were underexpressed. It should be pointed out that a few thyroid-related genes previously described to be deregulated in thyroid tumors, e.g., TSHR, NIS, DIO1 and DIO2, were not present on the filter array we used.
Genes displaying expression differences between PTC and FTC. One of our main aims was to identify genes expressed differentially in the two types of thyroid carcinomas in order to facilitate the discovery of critical genes for the different development pathways of thyroid carcinomas. On the basis of significant expression variation, 123 genes including 45 known genes and 78 unknown genes were identified to be differentially expressed between PTC and FTC. Strikingly, these genes displayed similar expression patterns between Table II . Continued.
Gene symbol Function and description 
The listed genes were differentially expressed between papillary thyroid carcinomas (PTC) and follicular thyroid carcinomas (FTC), significant at P<0.01 by Student's t-test.
b All accession numbers are from GenBank at the NCBI. c Percentage of tumors with 2-fold or greater alterations.
d These genes were frequently up-regulated in one tumor group and down-regulated in the other group. Table III . A list of genes differentially expressed in widely invasive FTC and/or the follicular carcinoma with anaplastic foci a . Table II . Using permutation 2-sample t-test to determine genes that were most differently expressed between two tumor groups, we identified 19 'most significant' genes, among which there were 7 known genes (BMP7,
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CEACAM7, CNN3, LHX1, MAP2K5, WRCH-1 and ZFP36L1).
Other genes displaying major differential expression between the two types of thyroid tumors included CTSH, GFER, GPC1, HLA-B, SERPINA1, TMSB4X and ZBTB3. These genes were frequently overexpressed in PTC but underexpressed in FTC. In addition, several genes that were previously reported to be involved in cancer development, e.g., BSG and FN1 (22, 23) , showed slightly differential expression between PTC and FTC (0.05>P<0.01). FN1 that is related with cell adhesion and extracellular matrix was highly increased in 81% of PTCs and 33% of FTCs, respectively. BSG, a cell surface antigen, was overexpressed in FTC but not in PTC.
Comparison of gene expression among subtypes. Follicular variant of PTC and classical PTC showed very similar gene expression patterns. Only a small set of genes displayed statistically significant expression differences between the two subtypes (data not shown). However, a clear segregation of the two subtypes was not established either by hierarchical clustering analysis or by immunohistochemical analysis. Genes that were found to be highly expressed in follicular variant PTC but not in classical PTC included CCNA2, CLPP, CENTB5, CTSH, DLG5, GFER, F2RL3, GPC1, IGHM, MAP3K10, MGC3036, MGC5178, PPARBP, SURF4 and ZYG. Several genes such as DSIPI, SRRM2, SDS, KIAA0947 and KIAA1464 were underexpressed in these follicular variants of papillary carcinoma compared with classical PTC.
In contrast to the PTC subtypes, gene expression alterations of FTC subgroups appeared to be well correlated to the tumor progression of FTC. Although the limited number of tumors is not suitable for statistical analysis, direct comparison revealed expression differences among the subtypes of FTC. A total of 80 genes were detected, for which expression ratios of widely invasive FTC vs. minimally invasive FTC reached >3-fold. In comparison with normal thyroid tissues, most of these genes were not differentially expressed in minimally invasive FTC but were underexpressed in widely invasive FTC (Table III) . Several genes were overexpressed in widely invasive FTC. Furthermore, 212 genes were identified to show >3-fold variations between the single follicular carcinoma with anaplastic foci and minimally invasive FTC. Many of these genes showed overexpression in this tumor.
Hierarchical cluster analysis of thyroid cancer samples. Twodimensional hierarchical cluster analysis of the selected 123 Table III . Continued. 
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a Considering mean value, these genes were not differentially expressed in minimally invasive follicular thyroid carcinomas.
b All accession numbers are from GenBank at the NCBI.
c Ratio of mean value of the two widely invasive follicular thyroid carcinomas (WiFTC) versus mean value of the ten minimally invasive follicular thyroid carcinomas (MiFTC).
d Ratio of the single follicular carcinoma with anaplastic foci (FTCa) versus mean value of the ten minimally invasive follicular thyroid carcinomas (MiFTC).
genes was performed to determine the relationship of the examined thyroid cancer samples on the basis of their gene expression profiles (Fig. 1) . The 29 tumors examined fell into two major groups, as shown by the two branches of the dendrogram in Fig. 1, top . The group at the left includes all PTC samples, whereas the group at the right consists of FTC samples. Using permutation 2-sample t-test, we demonstrated that all of the 123 genes were at a significant level for segregating PTC from FTC samples. These genes together gave an overall significance value of P=0.000058, supporting the potential use of the identified gene set in the histologyassociated classification of the two tumor types. However, the hierarchical clustering cannot distinguish between subtypes, suggesting that these genes might only differentiate the papillary from the follicular feature of thyroid cancer. The follicular carcinoma with anaplastic foci was clustered together with all FTCs, representing the genetic feature of a follicular growth of this tumor.
Validation of data. Repeated analyses of a single tumor RNA probe on 4 different filter arrays showed that approximately 95% of data points fell within 2-fold limits. The variations in our repeated analyses were lower than these previously reported by others (32) . This cross-validation procedure confirmed the high reproducibility of the filter-array approach that we used (Fig. 2) . In addition, we selected four genes (FN1, PAX8, TG and CNN3) to verify the array results by using relatively quantitative real-time PCR (Fig. 3) . The results obtained from both methods were in general consistent for all four genes.
Discussion
Using cDNA array analyses, we revealed both similarities and differences in the gene expression profiles of PTC and FTC. The majority of genes with altered expression were detected in PTC as well as in FTC. The shared molecular characteristics parallel the close histological and biological relationship of the two types of tumor. Genes displaying an aberrant expression in most of these cancers may play a causal role in thyroid cell transformation and might represent potential targets for developing novel strategies for prevention and treatment of thyroid cancer.
One of the striking findings is the involvement of the RAS pathway in the development of both PTC and FTC. The RAS gene family includes at least 21 members. They code for small GTPases that act as molecular switches, cycling between an inactive GDP-bound state and an active GTPbound state. They are activated in response to a wide variety of extracellular stimuli and regulate signaling pathways that control multiple biological processes. Mutations of RAS genes have been found in a variety of human tumors including thyroid cancer (33) (34) (35) . In our study, several RAS family genes (e.g., NRAS, RAB11B and RAB40C) were highly expressed, while others (BRAF, RAB1A and RAP1A) were underexpressed in both PTC and FTC. The findings support that disturbance of the RAS signaling pathway may play a role in the early transformation of thyroid malignancies. In a study on gene expression profiles of papillary thyroid carcinomas, which harbored BRAF, RAS or RET/PTC mutations, Giordano et al revealed a strong relationship between mutational status and gene expression, suggesting mutations of genes in the RAS signaling pathway could confer tumors with discrete mutationspecific phenotypical and biological features (36) .
Additional oncogenes including MET were shown to be overexpressed in the two common types of thyroid cancer, consistent with previous studies (22, 23, 29, 37, 38) . MET is a proto-oncogene encoding the hepatocyte growth factor (HGF) receptor. Various mutations in the MET gene have been reported to be associated with human tumors, such as papillary renal carcinoma and hepatocellular cancer (39, 40) . It is known that mutation of an oncogene may induce a conformation change of the protein that it encodes, thereby leading to oncogenic activation (41) . This kind of activating mutation may not significantly influence the transcript level. This could explain why some frequently mutated genes and fusion genes (e.g., RET/PTC and PAX8-PPARÁ1), involved in thyroid tumorigenesis, were not detected by gene expression profiling (24, 27, 28, 37) . However, the mutated gene may affect downstream targets in the signaling pathway, generating a distinct gene expression profile (42) .
Previous studies have suggested that several genes such as LGALS3 and FN1 can be used as markers for malignant transformation of thyroid tumors. The LGALS3 gene encodes galectin-3 (GAL3), a ß-galactosil-binding lectin involved in regulating cell-cell and cell-matrix interactions, whereas FN1 codes for fibronectin, an extracellular matrix protein. The overexpression of both genes is believed to be associated with malignant transformation of thyroid follicular cells (43) . In the present study, we showed an increase in the expression of both genes in the two common thyroid malignancies, supporting the potential diagnostic use of these genes as markers.
The underexpression of thyroid-specific genes including TG has been also suggested as a marker for thyroid malignancy. TG gene encoding thyroglobulin (the glycoprotein precursor of thyroid hormones) was found to be underexpressed in both PTC and FTC in our study. Interestingly, the underexpression of TG concurred with a decreased transcript level of PAX8, a member of the PAX family of transcriptional factors. PAX8 was shown to be able to activate expression of endogenous thyroid-specific genes including TG (44, 45) . PAX8 can also activate the promoter of TG by cooperating with thyroid transcription factor-1. The ability of PAX8 to activate transcription of thyroid-specific genes strongly suggests an important role of this transcription factor in the maintenance of functional differentiation in thyroid cells. A decreased expression of the PAX8 gene in thyroid cancer was also observed by others (46) . Efforts to clarify whether the underexpression of PAX8 is induced through mutation of this gene or other mechanisms could provide important information about the role of PAX8 in thyroid tumorigenesis.
The present study further detected genes that had not been previously reported in thyroid tumors. Some of these genes, e.g., PTPRF, RBBP6, TNFAIP6 and MMP12, are known to be related to human tumor development and metastasis. A few genes, including CCND3, TNK2 and CARD6, are associated with cell cycle, proliferation and signaling transduction. Thus, our results provide a useful source for further investigation of the biology of papillary and follicular thyroid cancers. Further studies to clarify whether the expression alterations of these genes identified by cDNA arrays are relevant for thyroid tumorigenesis could provide valuable data.
An important goal of this study is the identification of genes differently expressed between PTC and FTC, which may lead to the discovery of crucial genes associated with the development of papillary and follicular phenotypes. We found a molecular distinction between PTC and FTC on the basis of 123 differentially expressed genes, including 45 known genes and 78 ESTs, as shown by hierarchical clustering analysis. These differently expressed genes fall into different function categories including cell adhesion and extracellular matrix, membrane components, transcription regulation, signal transduction, cell cycle and growth regulation, nuclear acid structure and configuration, etc. In spite of displaying significant expression differences between PTC and FTC, none of these genes was consistently deregulated in all samples of one tumor type but not in the other. This implicates that many genes may somehow interact and thereby contribute to the complex molecular events responsible for the papillary and follicular phenotypes, respectively. It is striking that all tumors with papillary feature can be differentiated from those showing follicular phenotype by gene expression profiling. Although the histological features of PTC and FTC are usually quite distinct, the ability of gene expression profiling to distinguish the follicular variant of PTC from FTC is especially of potential clinical value. Detailed investigation of the differentially expressed genes could further elucidate the molecular events contributing to PTC and FTC development. Aldred et al recently compared two data sets, which were separately generated from two previous studies on PTC and FTC, and generated distinctive expression profiles of PTC and FTC (27) . They even showed that a minimum of five genes were able to distinguish PTC from FTC. Many genes including the 5 genes (CITED1, CLDN10, CAV1, CAV2 and IGFBP6) they detected, however, were not present in the cDNA arrays that we used. This made it difficult to compare their data with ours. It was reported that different microarray platforms could deliver conflicting data (47) . Therefore, there is a need for establishing standards for the microarray technology.
Our data demonstrate that follicular variants and classical PTCs share a very similar expression profile. Only a small number of genes were statistically differentiated between the follicular variant and classical PTC. Immunohistochemistry and hierarchical clustering analysis of these genes, however, failed to separate the two subtypes. In fact, most of these genes showed only slight, albeit statistically significant, alterations at the transcript level. The slight transcript changes might result in very small differences in protein expression between follicular variants and classical PTC, which are usually undetectable on immunohistochemistry or immunoblotting. In contrast to the PTC subtypes, widely invasive and minimally invasive FTC showed significant differences in gene expression. Especially, the follicular carcinoma with anaplastic foci displayed more expression alterations than both widely invasive and minimally invasive FTC. The findings seem to be in agreement with the clinical and biological behavior of these tumors. However, additional studies on large series of samples of each group are required to generate reliable data.
In conclusion, we have identified gene expression alterations either shared by PTC and FTC or occurring differently between the two tumor types. The shared expression alterations reflect a close histological and biological relationship between PTC and FTC. The genes displaying different expression between the two common tumor types may contribute to the progression of thyroid cancer in separate pathways. Differentiation of follicular variant PTC from FTC by gene expression is of potential clinical value. Gene expression profiling also revealed genes that were differentially expressed between widely and minimally invasive FTC. Since the segregation of thyroid tumor samples based on expression profiles was consistent with histological features, gene expression profiling may prove to be a potential molecular tool to distinguish the distinct types of thyroid cancer.
